Floatz logo

Therapeutic Asset Ratings

3,272 results matching 1 filter

91,564 assets · 7,904 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Ensartinib
Rhabdoid Tumor
National Cancer Institute (NCI)P2CCC (53)
Ensartinib
Soft Tissue Sarcoma
National Cancer Institute (NCI)P2CCC (53)
Ensartinib
Refractory Malignant Neoplasm
National Cancer Institute (NCI)P2CCC (53)
Ensartinib
Wilms Tumor
National Cancer Institute (NCI)P2CCC (53)
Epoetin Alfa
Acute Myeloid Leukemia With Multilineage Dysplasia
National Cancer Institute (NCI)P2CCC (53)
Epoetin Alfa
Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome
National Cancer Institute (NCI)P2CCC (53)
ERIBULIN MONOMETHANESULFONATE
Bladder Transitional Cell Carcinoma
National Cancer Institute (NCI)P2CCC (53)
ERIBULIN MONOMETHANESULFONATE
Renal Pelvis Urothelial Carcinoma
National Cancer Institute (NCI)P2CCC (53)
ERIBULIN MONOMETHANESULFONATE
Ureter Transitional Cell Carcinoma
National Cancer Institute (NCI)P2CCC (53)
ERIBULIN MONOMETHANESULFONATE
Urethra Transitional Cell Carcinoma
National Cancer Institute (NCI)P2CCC (53)
ERIBULIN MONOMETHANESULFONATE
Urinary Bladder Cancer
National Cancer Institute (NCI)P2CCC (53)
ERIBULIN MONOMETHANESULFONATE
Ureter Cancer
National Cancer Institute (NCI)P2CCC (53)
ERIBULIN MONOMETHANESULFONATE
Urethra Cancer
National Cancer Institute (NCI)P2CCC (53)
ERIBULIN MONOMETHANESULFONATE
Malignant Renal Pelvis Neoplasm
National Cancer Institute (NCI)P2CCC (53)
Etoposide
Minimally Invasive Lung Adenocarcinoma
National Cancer Institute (NCI)P2CCC (53)
Etoposide
Lung Superior Sulcus Carcinoma
National Cancer Institute (NCI)P2CCC (53)
EXEMESTANE
Maligant Granulosa Cell Tumor Of Ovary
National Cancer Institute (NCI)P2CCC (53)
FAPI74
Mesothelioma
National Cancer Institute (NCI)P2CCC (53)
FAPI74
Pheochromocytoma-Paraganglioma
National Cancer Institute (NCI)P2CCC (53)
FAPI74
Small Cell Lung Carcinoma
National Cancer Institute (NCI)P2CCC (53)
FES F-18
Progesterone-Receptor Negative Breast Cancer
National Cancer Institute (NCI)P2CCC (53)
Fexagratinib
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Fexagratinib
Breast Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Fexagratinib
Cervical Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Fexagratinib
Colon Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Showing 1326 to 1350 of 3,272 assets
PreviousPage 54 of 131Next